logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Mid 2019
Sesen Bio Inc
12-month data from phase III trial of Vicinium (VISTA)
High grade non-muscle invasive bladder cancer (NMIBC)
Mid 2019
VBI Vaccines Inc.
Pivotal Phase 3 clinical program for Sci-B-Vac to evaluate the safety and immunogenicity (PROTECT)
Hepatitis B
Mid 2019
VBI Vaccines Inc.
Pivotal Phase 3 clinical program for Sci-B-Vac to demonstrate lot-to-lot consistency for immune response (CONSTANT)
Hepatitis B
Mid 2019
Nightstar Therapeutics plc
Preliminary Data from expansion study of phase I/II clinical trial of NSR-RPGR (XIRIUS)
X-Linked Retinitis Pigmentosa (XLRP)
Mid 2019
Caladrius Biosciences, Inc.
Final results from phase II clinical trial of CLBS12
Critical limb ischemia
Mid 2019
Idera Pharmaceuticals, Inc.
Top line data from phase I/II trial of Tilsotolimod in combination with Ipilimumab(ILLUMINATE-204)
PD-1 refractory melanoma
Mid 2019
Conatus Pharmaceuticals Inc
Top-line results from phase IIb clinical trial of Emricasan (ENCORE-LF)
NASH cirrhosis patients
Mid 2019
VistaGen Therapeutics Inc
Topline results from phase II study of AV-101 (ELEVATE)
Depressive disorder
Mid 2019
VBI Vaccines Inc.
Top-line data from phase III study of Sci-B-Vac (PROTECT)
Prophylactic hepatitis B vaccine
Mid 2019
Intec Pharma Ltd.
Top line data from pivotal phase III clinical trial evaluating safety and efficacy of Accordion Pill
Advanced Parkinson's disease
Mid 2019
Synlogic Inc
Topline data from phase 1b/2a clinical trial of SYNB1020
Cirrhosis and elevated ammonia
Mid 2019
Synlogic Inc
Topline data from phase 1/2a study of SYNB1618
Phenylketonuria
Mid 2019
Celyad SA
Preliminary data from Phase 1 trial of CYAD-0 (DEPLETHINK)
relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients
Mid 2019
Aridis Pharmaceuticals Inc
Top-line results from phase II trial of AR-105
Acute pneumonia caused by P. aeruginosa infection
Mid 2019
Allakos Inc.
Top-line data from phase II trial of AK002 (ENIGMA)
Eosinophilic gastritis with or without eosinophilic gastroenteritis
Mid 2019
Autolus Therapeutics plc
Updated safety and preliminary efficacy data from phase I clinical trial of AUTO1 (ALLCAR19 study)
Adult patients with ALL
Mid 2019
Alnylam Pharmaceuticals Inc.
Topline results from phase III study of Inclisiran (ORION)
Hypercholesterolemia
Mid 2019
Alnylam Pharmaceuticals Inc.
Topline results from Phase III confirmatory trial of Inclisiran (ORION -9)
Heterozygous familial hypercholesterolemia
Mid 2019
Alnylam Pharmaceuticals Inc.
Top line results from Phase III confirmatory trial of Inclisiran in the U.S. (ORION-10)
Reduce LDL-cholesterol in patients with atherosclerotic cardiovascular disease
Mid 2019
Alnylam Pharmaceuticals Inc.
Top line results from phase III confirmatory trial of Inclisiran in the Europe (ORION-11)
Reduce LDL-cholesterol in patients with atherosclerotic cardiovascular disease
Mid 2019
Gritstone Oncology, Inc.
Submission of IND for SLATE-001
Immunotherapy candidate using shared neoantigens for “off-the-shelf” therapy
Mid 2019
AzurRx BioPharma, Inc.
Initial top-line data from phase II study of MS1819-SD (OPTION)
Cystic fibrosis patients with exocrine pancreatic insufficiency
May 2019
Audentes Therapeutics, Inc.
Clinical data update from phase I/II trial of AT132 (ASPIRO)
X-Linked Myotubular Myopathy
Mid 2019
Achieve Life Sciences Inc.
Topline efficacy and safety data from phase IIb optimization trial of Cytisinicline (ORCA-1 study)
Smoking cessation
Q2 2019
Constellation Pharmaceuticals, Inc.
Interim data update from phase II trial of CPI-0610 (MANIFEST)
Myelofibrosis